XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.2
Segment Information
 6 Months Ended
Jun. 28, 2024
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
The Company operates and reports its results in business segments consisting of the Biotechnology, Life Sciences and Diagnostics segments. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.
Segment results are shown below ($ in millions):
 Three-Month Period EndedSix-Month Period Ended
June 28, 2024June 30, 2023June 28, 2024June 30, 2023
Sales:
Biotechnology$1,713 $1,885 $3,237 $3,749 
Life Sciences1,770 1,796 3,515 3,505 
Diagnostics2,260 2,231 4,787 4,607 
Total$5,743 $5,912 $11,539 $11,861 
Operating profit:
Biotechnology$462 $480 $787 $1,076 
Life Sciences233 340 468 661 
Diagnostics556 424 1,386 1,101 
Other(83)(81)(161)(158)
Total$1,168 $1,163 $2,480 $2,680